Catalyst Pharmaceuticals, Inc. (CPRX) — 10-Q Filings
All 10-Q filings from Catalyst Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Catalyst Pharma Soars: Revenue Up 25%, Net Income Jumps 50%
— Nov 5, 2025 Risk: medium
Catalyst Pharmaceuticals, Inc. (CPRX) reported robust financial performance for the nine months ended September 30, 2025, with total revenues increasing by 24.7 -
Catalyst Pharma Sees Q2 Revenue Jump 7.1% on Product Sales
— Aug 6, 2025 Risk: medium
CATALYST PHARMACEUTICALS, INC. reported product revenue of $97.8 million for the three months ended June 30, 2025, compared to $91.3 million for the same period -
Catalyst Pharmaceuticals Files Q1 2025 10-Q
— May 7, 2025 Risk: medium
Catalyst Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations. K -
Catalyst Pharma Q3: Strong Royalties, Capital Gains
— Nov 6, 2024 Risk: medium
Catalyst Pharmaceuticals, Inc. reported its third quarter 2024 results for the period ending September 30, 2024. The company's revenue from sales of Firdapse an -
Catalyst Pharma Q2 Revenue Up, Acquires FYCOMPA Rights
— Aug 7, 2024 Risk: medium
Catalyst Pharmaceuticals, Inc. reported its Q2 2024 results, ending June 30, 2024. The company generated $196.6 million in net product revenue for the six month -
Catalyst Pharma Q1: FYCOMPA® Distribution Shift, Santhera Payment Complete
— May 8, 2024 Risk: low
Catalyst Pharmaceuticals, Inc. reported its first quarter 2024 results, ending March 31, 2024. The company fully paid the $5.9 million related to an investment
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX